A novel hemostatic agent was prepared using phosphoryl oligosaccharides of calcium (POs-Ca), hydroxyapatite [Ca 10 -(PO 4 ) 6 (OH) 2 ; HAp] obtained by the hydrolysis of POs-Ca (i.e., sugar-containing HAp (s-HAp), Ca/P ratio = 1.56, 60.3 mass% calcium-deficient HAp and 39.5 mass% organic materials) and thermoplastic resin (random copolymer of ethylene oxide and propylene oxide; EPO). The gel formed by mixing the EPO with water (EPO/water mass ratio: 0.20) was flash frozen at ¹80°C and then freeze-dried at ¹50°C for 15 h. The freeze-dried material was blended with POs-Ca or s-HAp. The hemostat, whose consistency had been adjusted to that of commercial hemostat by adding water, possessed the stanching times: 6.0 h (s-HAp/EPO hemostat; s-HAp/EPO = 0.20) > 5.75 h (POs-Ca/EPO hemostat; POs-Ca/EPO = 0.20) > 4.75 h (EPO hemostat). The test for the implantation of these composite hemostats into the Japanese white rabbits indicated that the bone regeneration of s-HAp/EPO composite hemostat was excellent, compared to the case of POs-Ca/EPO composite hemostat. The loading of gentamicin, a typical antibiotic agent, to the s-HAp/EPO composite hemostat showed the steady state releasing in the phosphate buffered saline.
Introduction
When bones are cut open during at a surgery, a large amount of bleeding occurs from the bone's vessel. There are three techniques to stop bleeding, (i) thermal hemostasis, (ii) mechanical hemostasis, and (iii) chemical hemostasis. 1) Most useful hemostat is a bone wax, whose major component is beewax, which may stop bleeding by the mechanical hemostatis. Unfortunately, the hemostats practically used are not fully biocompatible and sometimes cause infection, because it is derived from animals. 2) On the other hand, a block copolymer of "ethylene oxide and propylene oxide" is now commercially available for filling the bone defects.
3), 4) The problem of it may be that the poor flexibility makes its utilization as a hemostat difficult. Taking into account the utilization of EPO for hemostat, the random copolymer of EPO must be favorable rather than the block form, because it has excellent flexibility and adhesion performances. The random copolymer of EPO (hereafter describes only as EPO) with excellent flexibility and adhesion, as well as the biocompatibility and infection prevention, are expected to be available as a novel hemostat.
The phosphoryl oligosaccharides of calcium (POs-Ca), which is available for edulcorant, is extracted from the potato starch. 5 ), 6) The advantages of POs-Ca may be that it has groups of Ca 2+ and PO 4 3¹ , which is the potential ability of re-calcification, and that it is easily dissolved in water; the maximum amount of POs-Ca dissolved in water is estimated to be 50 mass%. By making use of such advantages, the present authors 7) have prepared a sugar-containing hydroxyapatite [Ca 10 (PO 4 ) 6 (OH) 2 ; s-HAp] from POs-Ca solution through the hydrothermal treatment. Thus the POs-Ca, as well as its hydrolyzed materials (s-HAp, i.e., HAp and organic components), may be available as biomaterials. As shown above, the ideas of designing novel hemostatic agents are based upon the flexibility, adhesion, biocompatibility and infection prevention, as well as the stanching effect. Taking these performances into account, the authors paid attention to the development of a novel hemostat through the combination of POs-Ca, s-HAp and thermoplastic resin (EPO), as shown in Fig. 1 . On the basis of such background, the present paper describes the optimized preparation conditions of novel materials for stanching the blood, using POs-Ca, s-HAp and EPO.
Materials and methods
The starting materials used for the designing of hemostat were POs-Ca and EPO. The commercial POs-Ca was hydrolyzed by hydrothermally treating 10 mass% POs-Ca solution at a temperature between 100 and 110°C for 5 h. On the other hand, the commercial EPO was mixed with de-ionized water to form gel (mass ratio of EPO to water: 1.0) and allowed to stand for 1 to 2 d. This mixture was frozen at ¹80°C and then dried at ¹50°C for 9 to 20 h. The freeze-dried mixture was ground by using a mechanical mixer. The ground powder was sieved into three grain-size fractions, (i) 0.51.0 mm, (ii) 1.02.0 mm and (iii) over 2.0 mm.
In order to check the operation performance of gel, the consistency was examined measuring the spread size, after the gel was set between two plates and loaded with a mass of 500 g. The stanching of blood was evaluated by checking the time that the paper on the hemostat started to be wet by the simulated blood come out the top of a porous HAp cube (porosity of 70% and mean pore size of 200¯m), due to the capillary force. 8) The phase identification was carried out using an X-ray diffractometer (XRD; RINT 2000V/P, Rigaku Corp., Tokyo, 40 kV and 40 mA) with monochromatic Cu K¡ radiation and a Fourier transform infra-red spectrometer (FT-IR; 8600PC, Shimadzu, Kyoto). Phase changes during the heating from room temperature to 1200°C were examined by differential thermal analysis and thermogravimetry (DTA-TG; Model Thermo Plus TG8120, Rigaku, Tokyo). The specific surface area of the powder was measured by the BET method, using nitrogen (N 2 ) as the adsorption gas. The observation of the particles was conducted using a field-emission scanning electron microscope (FE-SEM: Model SU-8000, Hitachi, Tokyo) with an accelerating voltage of 5 kV or a transmission electron microscope (TEM: Model JEM-2011, JEOL, Tokyo; accelerating voltage, 200 kV). The chemical composition of the powder was examined using an energy dispersive electron X-ray microanalyzer (EDX; EX-210, Horiba, Kyoto), attached to the FE-SEM.
The composite hemostats were implanted in the femur and tibia of Japanese white rabbits for 4 or 9 weeks. The degree of bone regeneration was observed on the basis of the nondecalcified specimens prepared with a Villanueva bone stain, using an inverted microscope (Axiovert135, Carl Zeiss Japan, Tokyo). The releasing amount of gentamicin was evaluated by o-phthalaldehyde method. 9) Firstly, gentamicin sulfate (10 mg) was mixed with the gel (1 g). After the gentamicin-containing gel was immersed in the 10 cm 3 phosphate buffered saline [PBS(¹)] at 37.0°C for 10 h, the releasing behavior of gentamicin from the gel was examined by measuring the absorbance of the sample solution containing 2-propanol at 332.0 nm by using a spectrophotometer (BioSpec-1600, Shimadzu, Kyoto). In this experiment, PBS(¹) solution was replaced with new one at each sampling. 10 ), 11) 3. Results and discussion
Preparation of HAp from the hydrothermallytreated POs-Ca
In order to prepare the HAp powder from POs-Ca, the hydrothermal treatment was conducted at a temprature between 100 and 110°C for 5 h. When the POs-Ca solution was hydrothermally treated at 105 and 110°C for 5 h, the precipitation occurred to form the powder. Although no precipitation occurred at the hydrothermal temperature of 100°C, the precipitates were instantaneously obtained by the addition of ethanol to the solution after cooling to room temperature. Figure 2 shows typical XRD patterns of hydrothermally treated powders at a temperature between 100 and 110°C for 5 h. XRD patterns of the hydrothermally-treated powders showed the presence of poorly crystallized HAp.
12)
The amounts of Ca and P of hydrothermally-treated powders were measured using an EDX. The molar ratio of Ca to P of the powder hydrothermally-treated at 100°C for 5 h was calculated to be 1.56. On the other hand, Ca/P ratios of the powders hydrothermally-treated at 105 and 110°C were 1.53 and 1.51, respec- tively. These analytical results indicate that the hydrothermallytreated powders were composed of calcium-deficient HAp with the general formula of Ca 10¹x (HPO 4 ) x (PO 4 ) 6¹x (OH) 2¹x ·nH 2 O (0¯x < 1.0). Since the Ca/P ratio of powder hydrothermallytreated at 100°C for 5 h was 1.56, the calcium-deficient HAp, for example, can be expressed as Ca 9.36 (HPO 4 
As the XRD patterns indicate, the presence of poorlycrystalline HAp suggests that the amorphous materials or organic materials must be present in the hydrothermally-treated powders. Figure 3 shows the FT-IR spectra showing the phases present in the hydrothermally-treated powders. FT-IR spectra of the powders hydrothermally treated at 100110°C for 5 h showed absorption peaks at around 570, 600, 870, 960, 1050, 1425, 1460 (shoulder) and 1650 cm ¹1 , together with the broad absorption band in the range of 3200 to 3700 cm ¹1 . The absorption peaks at 570, 600, 960 and 1050 cm ¹1 are assigned to the PO 4 3¹ in the HAp structure. The absorption peak at 1650 cm ¹1 and the absorption band in the range of 3200 to 3700 cm ¹1 are assigned to the physically-adsorbed water and the hydroxyl group in the HAp and POs-Ca. 13) Relating to the presence site of CO 3 2¹ in HAp structure, the characteristic absorption peaks at 880, 1450 and 1545 cm ¹1 may be regarded as the substitution site of "Type A", i.e., substitution of CO 3 2¹ for OH ¹ site in HAp, whereas the absorption peaks at 870, 1410 1420 and 14601470 cm ¹1 are regarded as the substitution site of 'Type B", i.e., substitution of CO 3 2¹ for PO 4 3¹ site in HAp. Further, the substitution of CO 3 2¹ for both OH ¹ and PO 4 3¹ sites is regarded as 'Type AB", whose absorption peaks appeared in the ranges of 850890 cm ¹1 and 14001650 cm
¹1
. Based upon the present data, we considered that the carbonate ions are partly substituted for the site of OH in HAp structure, i.e., Type B. 14) Figure 4 shows the changes in specific surface area of the powder with hydrothermal temperature, together with typical TEM micrographs. The specific surface area of the powder exponentially increased from 4.0 to 42.2 m 2 ·g ¹1 with increasing temperature from 100 to 110°C for 5 h. TEM micrograph of the powder hydrothermally-treated at 100°C for 5 h showed that the small particles with sizes of approximately 20 nm were stuck together to form aggregates. On the other hand, TEM micrograph of the powder hydrothermally-treated at 110°C for 5 h showed that the small particles with sizes of approximately 2 nm were stuck together to form aggregates.
Compared to the particle sizes of the powders hydrothermallytreated at 100 and 110°C for 5 h, the former particles sizes appeared to be larger than the latter particle sizes. This phenomenon is not so surprising, since the particle size of HAp was larger with increasing temperature. The larger particle size of the powder hydrothermally-treated at 100°C for 5 h may be achieved by the adhesion of small HAp particles, due to the presence of POs-Ca derived organic compound.
The results obtained so far indicate that the hydrothermallytreated powers may contain not only calcium-deficient HAp but organic components. In addition to the phase identification conducted by XRD and FT-IR, the presence and amount of organic components were examined using the DTA-TG and XRD. The results are shown in Fig. 5 . On the basis of DTA results of the powder hydrothermally-heated at 100°C for 5 h, the broad exothermic events occurred over the range of 200 to 550°C [solid line in Fig. 5(a) ]. On the other hand, DTA curve of POs-Ca contained the broad exothermic events in the range of 200 to 450°C and 450 to 700°C [dotted line in Fig. 5(a) ]. On the basis of the phase changes examined by XRD, X-ray intensity of HAp started to be reduced above 500°C and became almost zero at 700°C, whereas ¢-TCP, 15) which appeared at 500°C, increased with temperature [ Fig. 5(b) ]. Further, TG results showed that the step-wise mass losses occurred in the ranges of 200 to 500°C and 500 to 800°C [ Fig. 5(c) ].
According to the DTA-TG and XRD results, the phase changes during the heating of s-HAp may be occurred by the routes of (1) the formation of carbon through the thermal decomposition of hydrothermally-treated powder were shifted toward the lower temperature, compared to the case of POs-Ca powder.
Optimization for the fabrication conditions of hemostat
The consistency of the commercial hemostat measured in this research was 18.2 mm. Figure 6 shows the effect of grain size on the consistency of the present EPO hemostat, as a function of the amount of water. The overall trend showed that the consistency of EPO hemostat increased from 14.5 to 18.5 mm with increasing amount of water, and that no marked difference in consistency was found, independent of the grain sizes of EPO, i.e., (i) 0. The changes in consistency of POs-Ca/EPO composite hemostat containing various amounts of POs-Ca were further measured by changing POs-Ca/EPO ratio and amount of water. The results are shown in Fig. 7 . The overall trend showed that the consistency of the composite hemostat increased with increasing POs-Ca/EPO ratio and amount of water addition. Taking notice of the water content, the steady-state increase in consistency was found after the rapid increase in consistency at the initial stage of water addition.
The addition of POs-Ca contributes to enhancing the consistency of composite hemostat. This phenomenon is explained by assuming that the high dissolution of POs-Ca in water may enhance the fluidability of EPO, thereby showing the higher consistency. On further increase in the amount of water, the slopes of the linear relationship between amount of water and consistency of POs-Ca/EPO hemostat are in accordance with the case of pure EPO hemostat. The linear regression analysis and fitting indicate a: 1.621.77, b: 13.9118.80 and R 2 (coefficient of determination): 0.93530.9873. The present data agree well with those of EPO hemostat, and the consistencies of POs-Ca/ EPO composite hemostats in the parts of straight lines are found to be dependent upon the consistency of EPO.
We considered that the optimum POs-Ca/EPO ratio for the consistency control is 0.2, because the consistency of POs-Ca/ EPO composite hemostat may be controlled over the wider range of water to powder ratio (i.e., 0.5 to 4.0). The changes in consistencies of EPO, POs-Ca/EPO composite and s-HAp/EPO composite hemostats with the amount of water are shown in Fig. 8 . The overall trend showed that the consistency of POs-Ca/ EPO composite hemostat increased with increasing amount of water, but that the consistency of s-HAp/EPO composite hemostat remained unchanged, regardless of the increase in amount of s-HAp.
The linear regression analysis and fitting to the case of POs- Ca/EPO composite hemostat indicate a = 1.70x + 18.8, whereas those of s-HAp/POs-Ca show a = 0.43x + 15.0. The significant increase in consistency was found for the case of POs-Ca/ EPO composite hemostat, compared to the case of s-HAp. As already mentioned, the fluidability of EPO seems to be enhanced by the dissolution of POs-Ca in water, thereby enhancing the consistency.
Properties of composite hemostats
Since the POs-Ca/EPO and s-HAp/EPO composite hemostats could be prepared under the optimized conditions, the properties of resulting hemostats were examined in this section. The stanching times of the composites were: 6.0 « 0.5 h (s-HAp/ EPO) & 5.75 « 0.25 h (POs-Ca/EPO) > 4.75 « 0.25 h (pure EPO). The time for surgery operation is estimated to be 2 to 3 h, indicating that the time for stanching the blood may be satisfactory for the utilization as a hemostat. Since the POs-Ca and EPO are water soluble, the stanching performances of the EPO and POs-Ca/EPO composite hemostats seem to be reduced by the instantaneous penetration of simulated blood in the space formed with the dissolution of POs-Ca and EPO.
These hemostats were implanted in the femur and tibia of the Japanese white rabbit. The microscopic examination of the specimens in the femur and tibia of the Japanese white rabbit was conducted using the sectioned specimen (Villanueva bone stain). The photographs and optical micrographs of sectioned specimens after the implantation of them in the periods of 4 and 9 weeks are shown in Fig. 9 . The results on the implantation for 4 weeks showed that the significant bone regeneration, together with the formation of osteoid (see the arrow marks), was found for the case of s-HAp/EPO composite and EPO hemostats, compared to the case of POs-Ca/EPO composite hemostat. On further increase in implantation period to 9 weeks, the bone regeneration was significant for the POs-Ca/EPO composite hemostat within the femur and tibia, as well as the case of s-HAp/EPO composite and EPO hemostats.
For the sample with the implantation for 4 weeks, the retarded born regeneration for the case of POs-Ca/EPO composite hemostat may be attributed to the rapid dissolution of POs-Ca at the initial stage of implantation. Nevertheless, the significant bone regeneration is found for the case of POs-Ca/EPO composite hemostat after the implantation for 9 weeks. As is the case of implantation for 4 weeks, the excellent bone regeneration is found for the s-HAp/EPO composite and EPO hemostats, in contrast to the case that parts of the original hemostat remained when the commercial bone wax was implanted into the femur and tibia of Japanese white rabbits for 9 weeks (not shown here).
Further, we incorporated gentamicin, a typical antibiotic, into these hemostats, and examined the releasing behavior of it into the PBS(¹). The releasing behaviors of gentamicin from the composites in the PBS(¹) are shown in Fig. 10 . The overall trend reveals that gentamicin was released with increasing immersion time to 10 h. The amounts of gentamicin were classified as follows: POs-Ca/EPO hemostat (424.1 mg·cm ¹3 ) > EPO hemostat (230.6 mg·cm
¹3
) > s-HAp/EPO hemostat (172.0 mg·cm ¹3 ). It should be noted that the steady state of gentamicin releasing was found in the case of s-HAp/EPO hemostat. This fact suggests that the amount of gentamicin released from the EPO may be controlled by using the s-HAp. In this case, HAp particles within s-HAp may contribute to adsorbing gentamicin, thereby retarding the release of it in PBS(¹).
In order to quantitatively check the drug releasing behavior, the data were fitted to typical kinetic equations, i.e., (i) zero-order equation 
Conclusion
Novel hemostatic agent was prepared using hydroxyapatite [Ca 10 (PO 4 ) 6 (OH) 2 ; HAp], thermoplastic resin (EPO) and POs-Ca. The drug releasing behavior of gentamicin in the PBS(¹) saline solution form the EPO was examined using the hemostat. The results obtained were summarized as follows:
(1) The starting EPO gel was obtained by the flash freezing at ¹80°C and then freeze-drying at ¹50°C for 15 h.
The freeze-dried materials were sieved in order to obtain the EPO powder with sizes of 1 to 2 mm. The nonstoichiometric HAp particles with the Ca/P ratio of 1.56, which had been prepared by hydrothermally heating the POs-Ca at 100°C for 5 h, were further mixed with EPO powder. Then the de-ionized water was put into the mixed powder to form the EPO gels with HAp in order to form the composite. (2) The test for the implantation of s-HAp/EPO hemostat into the Japanese white rabbits showed the excellent bone regeneration, compared to the case of POs-Ca/EPO composite hemostat. Moreover, the hemostat containing s-HAp and EPO (s-HAp/EPO = 0.20) was effective for the steady state releasing of gentamicin sulfate, as well as the inhibition of bleeding. 
